<DOC>
	<DOCNO>NCT00202982</DOCNO>
	<brief_summary>This study test new high dose Copaxone effective treat relapsing-remitting multiple sclerosis currently available 20 mg dose .</brief_summary>
	<brief_title>A Study Test Effectiveness Safety New Higher 40mg Dose Copaxone® Compared Copaxone® 20mg , Currently Approved Dose</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Clinically definite MS disease duration ( onset ) least 6 month . 2 . Subjects must least 1 documented relapse within last year prior study entry . 3 . Subjects must least 1 15 gadolinium ( Gd ) enhance lesion screen MRI scan . 4 . Subjects must relapsefree take corticosteroid ( IV , IM and/or PO ) within 30 day prior screen visit . 5 . Subjects must take corticosteroid ( IV , IM and/or PO ) screen baseline visit . 6 . Subjects may male female . Women child bear potential must practice medically acceptable method birth control . Acceptable method include oral contraceptive , contraceptive patch , doublebarrier method ( condom IUD spermicide ) . 7 . Subjects must age 18 50 year inclusive . 8 . Subjects must ambulatory , Kurtzke EDSS score 0 5 inclusive . 9 . Subjects must willing able give write informed consent prior enter study . 1 . Previous use glatiramer acetate ( oral injectable ) . 2 . Previous use cladribine . 3 . Previous use immunosuppressive agent last 6 month . 4 . Use experimental investigational drug , include I.V . immunoglobulin , and/or participation investigational drug study within 6 month prior study entry . 5 . Use interferon agent within 60 day prior screen visit . 6 . Chronic corticosteroid ( IV , IM and/or PO ) treatment ( 30 consecutive day ) 6 month prior study entry . 7 . Previous total body irradiation total lymphoid irradiation ( TLI ) . 8 . Pregnancy breast feed . 9 . Patients experience relapse screening ( month 1 ) baseline ( month 0 ) visit . 10 . Any condition investigator feel may interfere participation study , include alcohol and/or drug abuse . 11 . A known history sensitivity mannitol . 12 . A known sensitivity gadolinium . 13 . Inability successfully undergo MRI scanning .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>